ENFN vs. QTWO, TEM, INTA, BZ, VRNS, SOUN, FRSH, TENB, CLBT, and BOX
Should you be buying Enfusion stock or one of its competitors? The main competitors of Enfusion include Q2 (QTWO), Tempus AI (TEM), Intapp (INTA), Kanzhun (BZ), Varonis Systems (VRNS), SoundHound AI (SOUN), Freshworks (FRSH), Tenable (TENB), Cellebrite DI (CLBT), and BOX (BOX). These companies are all part of the "computer software" industry.
Enfusion vs.
Q2 (NYSE:QTWO) and Enfusion (NYSE:ENFN) are both computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
Q2 received 477 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 68.88% of users gave Q2 an outperform vote while only 19.61% of users gave Enfusion an outperform vote.
In the previous week, Enfusion had 15 more articles in the media than Q2. MarketBeat recorded 17 mentions for Enfusion and 2 mentions for Q2. Q2's average media sentiment score of 0.39 beat Enfusion's score of 0.29 indicating that Q2 is being referred to more favorably in the media.
Q2 currently has a consensus price target of $98.07, indicating a potential upside of 4.50%. Enfusion has a consensus price target of $10.25, indicating a potential downside of 7.28%. Given Q2's stronger consensus rating and higher possible upside, equities research analysts clearly believe Q2 is more favorable than Enfusion.
81.1% of Enfusion shares are held by institutional investors. 3.0% of Q2 shares are held by insiders. Comparatively, 36.4% of Enfusion shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Q2 has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
Enfusion has a net margin of 1.70% compared to Q2's net margin of -8.40%. Enfusion's return on equity of 6.67% beat Q2's return on equity.
Enfusion has lower revenue, but higher earnings than Q2. Q2 is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Summary
Q2 and Enfusion tied by winning 9 of the 18 factors compared between the two stocks.
Get Enfusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENFN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enfusion Competitors List
Related Companies and Tools
This page (NYSE:ENFN) was last updated on 1/20/2025 by MarketBeat.com Staff
Free ENFN Stock Alerts